Ratio Therapeutics Banks $70M to Push Radiopharma Trial and Build Out Pipeline

Ratio Therapeutics, a radiopharmaceutical company, has closed a $70 million Series C financing round. The firm develops targeted radiation therapies, and the new capital will be directed toward three specific priorities: advancing its ATLAS clinical trial, growing its pipeline of radiopharma candidates, and expanding manufacturing capacity. The round was announced on August 5, 2026, with no lead investors identified in the disclosure. The ATLAS trial serves as the company’s lead clinical program, though details on the indication, phase, and enrollment were not provided. Scaling manufacturing is a critical step for radiopharmaceutical developers, given the short half-lives of therapeutic isotopes and the need for reliable, just-in-time production and distribution. The $70 million infusion will allow Ratio to push that program forward while broadening its portfolio of targeted radiation therapies. The lack of a named lead investor could reflect a syndicate of existing backers or a strategic investment from undisclosed partners. The funding comes as the radiopharma sector continues to draw capital, with companies leveraging alpha and beta emitters to deliver precise radiation to tumors. Ratio’s ability to simultaneously fund a clinical trial and invest in manufacturing infrastructure underscores the capital-intensive nature of bringing these complex therapies to market.